Consolidative Radioimmunotherapy after Chemoimmunotherapy in Patients with Histologic Transformation of Indolent Non-Hodgkin Lymphoma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 16, Issue 6, 2016, Pages 322-328.e2

  Reagan, Patrick M ^a   Baran, Andrea ^a   Kelly, Jennifer L ^a   Barr, Paul M ^a   Casulo, Carla ^a   Chengazi, Vaseem U ^a   Friedberg, Jonathan W ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

131I tositumomab; 90Y ibritumomab tiuxetan; indolent lymphoma; radioimmunoconjugate; transformed lymphoma

Indexed keywords

BENDAMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHEMOIMMUNOTHERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPOSITE LYMPHOMA; CONSOLIDATIVE RADIOIMMUNOTHERAPY; CONTROLLED STUDY; FEMALE; FRACTURE; HISTOLOGIC TRANSFORMATION; HISTOLOGY; HUMAN; INFECTIOUS COMPLICATION; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCYTOPENIA; PATHOLOGY; PROGRESSION FREE SURVIVAL; RADIATION INJURY; RADIOIMMUNOTHERAPY; RETROSPECTIVE STUDY; STANDARD; SUBDURAL HEMATOMA; SURVIVAL RATE; THROMBOCYTOPENIA; CAUSE OF DEATH; CELL TRANSFORMATION; IMMUNOTHERAPY; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PROCEDURES; RETREATMENT; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAUSE OF DEATH; CELL TRANSFORMATION, NEOPLASTIC; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; RETREATMENT; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84964681150     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2016.03.014     Document Type: Article

References (31)

1. B.K. Link, M.J. Maurer, G.S. Nowakowski, and et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic specialized program of research excellence molecular epidemiology resource J Clin Oncol 31 2013 3272 3278
2. C. Casulo, W.R. Burack, and J.W. Friedberg Transformed follicular non-Hodgkin lymphoma Blood 125 2015 40 47
3. A.J. Al-Tourah, K.K. Gill, M. Chhanabhai, and et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma J Clin Oncol 26 2008 5165 5169
4. S. Montoto, A.J. Davies, J. Matthews, and et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma J Clin Oncol 25 2007 2426 2433
5. J.M. Foran, J. Apostolidis, D. Papamichael, and et al. High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre Ann Oncol 9 1998 865 869
6. C.I. Chen, M. Crump, R. Tsang, and et al. Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma Br J Haematol 113 2001 202 208
7. M.B. Eide, G.F. Lauritzsen, G. Kvalheim, and et al. High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study Br J Haematol 152 2011 600 610
8. D. Villa, M. Crump, T. Panzarella, and et al. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group J Clin Oncol 31 2013 1164 1171
9. D. Villa, M. Crump, A. Keating, and et al. Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation Ann Oncol 24 2013 1603 1609
10. M. Ban-Hoefen, A. Vanderplas, A.L. Crosby-Thompson, and et al. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database Br J Haematol 163 2013 487 495
11. J.W. Friedberg, D. Neuberg, J.G. Gribben, and et al. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies Biol Blood Marrow Transplant 5 1999 262 268
12. M. Ban-Hoefen, J.L. Kelly, S.H. Bernstein, and et al. High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era Leuk Lymphoma 53 2012 830 835
13. J.M. Vose, R.L. Wahl, M. Saleh, and et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas J Clin Oncol 18 2000 1316 1323
14. M.S. Kaminski, A.D. Zelenetz, O.W. Press, and et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas J Clin Oncol 19 2001 3918 3928
15. T.E. Witzig, L.I. Gordon, F. Cabanillas, and et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma J Clin Oncol 20 2002 2453 2463
16. R.I. Fisher, M.S. Kaminski, R.L. Wahl, and et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas J Clin Oncol 23 2005 7565 7573
17. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial J Clin Oncol 31 2013 1977 1983
18. P.L. Zinzani, E. Derenzini, C. Pellegrini, and et al. Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma) Ann Oncol 23 2012 805 807
19. O.W. Press, J.M. Unger, L.M. Rimsza, and et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016 J Clin Oncol 31 2013 314 320
20. P.L. Zinzani, M. Tani, S. Fanti, and et al. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients Ann Oncol 19 2008 769 773
21. J.W. Friedberg, J.M. Unger, W.R. Burack, and et al. R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433 Br J Haematol 166 2014 382 389
22. C. Madsen, M.B. Pedersen, M.O. Vase, and et al. Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation Ann Oncol 26 2015 393 399
23. P.L. Zinzani, M. Tani, A. Pulsoni, and et al. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ) Lancet Oncol 9 2008 352 358
24. S. Montoto Treatment of patients with transformed lymphoma Hematology 2015 2015 625 630
25. H.R. Guirguis, M.C. Cheung, E. Piliotis, and et al. Survival of patients with transformed lymphoma in the rituximab era Ann Hematol 93 2014 1007 1014
26. J.M. Bennett, M.S. Kaminski, J.P. Leonard, and et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab Blood 105 2005 4576 4582
27. M.S. Czuczman, C. Emmanouilides, M. Darif, and et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy J Clin Oncol 25 2007 4285 4292
28. G.K. Vincent, and V.A. Velkoff The Next Four Decades: The Older Population in the United States, 2010 to 2050: Population Estimates and Projections 2010 US Census Bureau Washington (DC)
29. A. Hurria, L.A. Levit, W. Dale, and et al. Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement J Clin Oncol 33 2015 3826 3833
30. A. Hurria, S. Gupta, M. Zauderer, and et al. Developing a cancer-specific geriatric assessment: a feasibility study Cancer 104 2005 1998 2005
31. A. Hurria, K. Togawa, S.G. Mohile, and et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study J Clin Oncol 29 2011 3457 3465